Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTriSalus Life Sciences Inc.

TriSalus Life Sciences Inc.

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
3.48 USD -0.15 ( 4.13%)
Last update at 2026-11-03T21:00:00Z
VOLUME
135002
Market Cap
214.56M

Momentum Score

…

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.40
Low
3.77
High
52 Week Price Range
3.32
Low
12.83
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

TriSalus Life Sciences appears to focus on developing medical technologies for locoregional cancer treatment based on public disclosures. Its long-term growth drivers include regulatory approvals, positive clinical outcomes, successful commercialization and reimbursement adoption in oncology care, and broader acceptance of minimally invasive therapies. Investors may find the company attractive because it targets a large cancer-treatment market and could benefit if its clinical and regulatory programs achieve validation.

Key risks include clinical and regulatory failure, limited operating history and revenues, ongoing capital needs and dilution, and strong competition from established oncology and medical-device companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.63
Dividend Yield
-
Revenue TTM
18.51M
Revenue Per Share
1.97
Gross Profit TTM
0.00M
Debt / Equity
-0.06
ROE
-496.21%
Net Debt
-10.18M
ROCE
-407.60%
Diluted EPS TTM
-2.60

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Income before tax -47.18M -28.84M
Net income -47.19M -28.84M
Selling general administrative 12.48M 8.75M
Selling and marketing expenses 12.74M 8.26M
Gross profit 10.14M 7.21M
Reconciled depreciation 0.40M 0.46M
Ebit -44.99M -23.29M
Ebitda -44.59M -22.82M
Depreciation and amortization 0.40M 0.46M
Operating income -36.44M -24.03M
Other operating expenses 48.84M 32.43M
Interest expense 0.00M 1.76M
Tax provision 0.01M 0.00M
Interest income 0.18M 0.00M
Net interest income 0.18M -1.76M
Income tax expense 0.01M 0.00M
Total revenue 12.40M 8.40M
Total operating expenses 46.58M 31.24M
Cost of revenue 2.26M 1.19M
Total other income expense net -10.92M -3.05M
Net income from continuing ops -47.19M -28.84M
Breakdown 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31
Total assets 25.73M 22.00M 252.01M
Intangible assets 1.13M - -
Other current assets 2.99M 0.21M 0.67M
Total liab 51.66M 198.32M 8.85M
Total stockholder equity -25.94M -176.33M 243.16M
Other current liab 0.39M 27.04M 0.10M
Common stock 0.00M 0.01M 238.16M
Capital stock 0.00M 0.01M 0.01M
Retained earnings -248.38M -186.36M -0.11M
Cash 11.78M 9.41M 1.33M
Total current liabilities 14.69M 32.36M 0.10M
Current deferred revenue 10.56M 6.38M -
Net debt -10.18M -7.45M -1.33M
Short term debt 0.35M 0.37M -
Short long term debt total 1.59M 1.96M 0.54M
Other stockholder equity 222.44M 10.02M 5.10M
Total current assets 20.86M 17.21M 2.01M
Net receivables 3.55M 1.56M 1.36M
Inventory 2.54M 1.47M 1.29M
Accounts payable 3.39M 4.95M 1.30M
Non currrent assets other 0.47M -19.46M 250.00M
Non current assets total 4.86M 4.78M 250.00M
Capital lease obligations 1.59M 1.96M 0.00M
Breakdown 2022-12-31 2021-12-31
Type yearly yearly
Date 2022-12-31 2021-12-31
Investments -1.79M -2.26M
Total cash from financing activities 13.46M 50.77M
Net income -47.19M -28.84M
Change in cash -20.64M 25.81M
Begin period cash flow 30.30M 4.49M
End period cash flow 9.66M 30.30M
Total cash from operating activities -32.31M -22.70M
Issuance of capital stock 13.50M 52.02M
Depreciation 0.40M 0.46M
Change to inventory -0.18M -0.72M
Change to account receivables -0.20M -0.74M
Other cashflows from financing activities 13.59M 52.12M
Capital expenditures 0.79M 1.26M
Change in working capital 2.30M -0.13M
Stock based compensation 0.37M 0.11M
Other non cash items 11.81M 5.71M
Free cash flow -33.10M -23.95M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
TLSI
TriSalus Life Sciences Inc.		 -0.15
4.13%		 3.48 - - 15.33 30.29 16.95 -5.96
ABT
Abbott Laboratories		 -
-%		 109.40 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -0.41
0.41%		 98.88 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 3.74
1.22%		 310.55 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 0.66
1.38%		 48.35 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

TriSalus Life Sciences Inc.

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

6272 West 91st Avenue, Westminster, CO, United States, 80031

303 442 1222

https://trisaluslifesci.com

112

Name Title Year Born
Ms. Mary T. Szela B.S.N., M.B.A. CEO, President & Director 1964
Mr. Sean Edward Murphy CFO & Director 1953
Dr. Steven C. Katz F.A.C.S., M.D. Chief Medical Officer & Chairman of Scientific Advisory Board 1975
Ms. Jennifer L. Stevens J.D. Chief Regulatory Officer 1961
Ms. Lori Ann Santamaria Vice President of Operations NA
Dr. Bryan F. Cox Ph.D. Chief Scientific & Manufacturing Officer 1962
Mr. James E. Young Senior VP of Investor Relations & Treasurer NA
Ms. Rachel Garcia Marketing Manager NA
Dr. Richard B. Marshak M.B.A., MBA, VMD Senior Vice President of Corporate Development & Strategy 1959
Ms. Jodi Devlin President of Commercial Operations 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…